Eterna Therapeutics Enters Into Licence Agreement with Lineage Cell Therapeutics
Wednesday, February 22, 2023
Eterna Therapeutics announced that it has entered into an exclusive option and licence agreement (the “Agreement”) with Lineage Cell Therapeutics (“Lineage”) for the development of novel induced hypoimmune pluripotent stem cell (iPSC) lines, which Lineage will evaluate for development into cell transplant therapies. The new cell lines developed by Eterna will support the potential creation of additional product candidates at Lineage, specifically for the treatment of certain central nervous system (CNS) disorders and other neurology indications.
Under the Agreement, Eterna plans to conduct certain gene-editing activities and provide materials to Lineage for evaluation. The Agreement provides Lineage an option to obtain an exclusive licence to utilise and sublicense the novel gene-edited cell lines for preclinical, clinical, and commercial purposes in the field of CNS diseases.
This agreement provides the opportunity to combine insights obtained from dry age-related macular degeneration programme with new tools, to broaden the scope of technology and thereby helps to deliver solutions for a wider range of diseases.
